NEW YORK (360Dx) – MRM Proteomics said Wednesday it is partnering with Exactis Innovation to develop a proteomic test for guiding cancer immunotherapy.

The test will be based on MRM Proteomics' immunoMALDI approach, which uses antibody enrichment of target proteins followed by analysis via MALDI mass spec. The company said it will use the approach to analyze breast and colorectal cancer samples in Exactis’ Personalize My Treatment patient registry to identify and validate protein markers predictive of patient response to cancer immunotherapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.